跳至主要内容
临床试验/NCT00566761
NCT00566761终止4 期

Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion

Asociación para Evitar la Ceguera en México2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2007年6月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
10
试验地点
2
主要终点
Changes in Best corrected visual acuity and macular edema measured with OCT

研究概览

简要总结

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

详细描述

Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Macular edema secondary to central retinal vein occlusion
  • BCVA worse than 20/40
  • Central macular >250 mc with OCT

排除标准

  • Diabetic retinopathy or other retinopathy
  • Media opacity that does not allow following
  • steroid responder
  • diagnosed glaucoma or IOP > 21 mmHg

结局指标

主要结局

Changes in Best corrected visual acuity and macular edema measured with OCT

时间窗: Follow up to 3 , 6 and 12 months

次要结局

  • Report treatment complications(12 month)

研究者

发起方
Asociación para Evitar la Ceguera en México
申办方类型
Other

研究点 (2)

Loading locations...

相似试验